Videos

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Harry P. Erba, MD, PhD, discusses the need to retest for mutations including IDH1, IDH2, FLT3, NPMI, and KMT2A rearrangement for patients with relapsed or refractory acute myeloid leukemia.

Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

A panel of clinical experts provide insights about the importance of molecular and cytogenetic testing in diagnosing acute myeloid leukemia and in determining the best treatment plan.

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.

Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.

Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.

Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.

Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.

Closing out their discussion on multiple myeloma, expert panelists share expectations and hopes for the future treatment paradigm.

Thought leaders from various institutions offered their closing thoughts the 2023 ASCO Annual Meeting.

Thought leaders from various institutions offered their shameless plug the 2023 ASCO Annual Meeting.

Thought leaders from various institutions offered their take on the biggest winner that came out of the 2023 ASCO Annual Meeting.

In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.

Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.

Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.

A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.

Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.

Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.